10-10-13 3:30 PM EDT | Email Article

LOS ANGELES, CA -- (Marketwired) -- 10/10/13 -- SK3 Group, Inc.'s (OTC Pink: SKTO) subsidiary, Medical Greens, is pleased to announce that it has obtained the exclusive license for Dharmanol™ for the State of California. Dr. Charles Apel of Berkeley Bio-Organic Research Laboratories has developed a proprietary technology to extract, stabilize, and preserve the medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. This technology allows patients to consume cannabinoid medicine without any of the "high" or "stoned" effects.

"We consider this to be a major breakthrough in the treatment of cancer using cannabinoids. The results seen by those groups and individuals promoting the use of what has been dubbed 'Simpson' therapy have been very convincing. The problem, however, has been that many people who are fighting cancer, and have no experience with cannabis, cannot take the emotional and mental effects that come from following the regimen, which requires consumption of a gram of cannabis extract oil every day for several months. This is the equivalent of smoking up to 100 marijuana cigarettes every day. The "high" from the experience is truly overwhelming, and we have seen patients choose to discontinue the therapy, even though doing so likely leads to negative effects on their treatment," said D. Gold, Dr. Apel's partner in development of the process. "Now patients will be able to consume the large doses necessary for this therapy to be effective, with none of the psychoactive side effects that have been such an unforgiving part of the therapy."

Dharmanol™ (pronounced DAR-mah-nol) will be available in two forms: low-dose non-psychoactive tablets and high-doses. The low-dose non-psychoactive tablets can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid system, an internal system which controls and regulates many other bodily systems such as immune response. Much research has shown that there is substantial medicinal benefit in "stimulating" a compromised endo-cannabinoid system with cannabinoids, causing the other systems to work as they should.

These tablets will contain an array of the most beneficial non-psychoactive cannabinoids. Each tablet will contain 5 mg. of CBD, 5 mg. of mixed cannabinoids in their non-psychoactive form (known as mixed carboxylates) and 5 mg. of a steam-distilled mixture of the natural terpenes and terpenoids found in cannabis and hemp. The terpene element is thought to be responsible for the increased medicinal efficacy of "whole plant" cannabis preparations.

At the opposite end of the spectrum is using high dosage Dharmanol™ much like the "Simpson" therapy. High doses can be taken daily with no psychoactive effects. On observing the positive results that patients are receiving with standard Simpson therapy, most people studying cannabis medicine agree that if the dose could be increased ten or a hundred times, its already substantial efficacy against cancer will be similarly enhanced. Now this is possible thanks to the removal of the "high" from the cannabinoids in the production of Dharmanol™.

"We believe that we have crossed the bridge, so to speak, between the incredible medicinal efficacy of the cannabis plant and the world of nutraceutical supplements. Now people will be able to benefit from the substantial health-giving aspects of the cannabis plant, without the 'high' and related side effects that have kept this wonderful herb from entering the world of mainstream medicine. Dr. Apel and I would like to thank all those who have worked so hard on this project to help us develop this new technology," said Gold.

"We are pleased to have acquired this exclusive license to this important new product in the fight against disease using medical cannabis," said Artemus Mayor, President of SK3 Group. "We expect it to be in high demand with collectives and consumers."

Dharmanol™ tablets will be distributed through the collectives managed by or partnered with Medical Greens, which currently has products in over 75 collectives in the state of California. The Manufacturer's Suggested Retail Price will be $25.00 per bottle for 8 capsules.

About SK3
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

FDA Disclaimer
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent disease. Use only as directed.

Investor Relations

Add a Comment

News   More...

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar

Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Content Partners
Morningstar - - SKTO's Medical Greens Announces Licensing Agreement for Revolutionary New High Dose MMJ Delivery Option Dharmanol(TM)
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Author |  Collection |  Interest |  Popularity

Previous: SKTO's Medical Greens Announces a New Product Line to Market Through Contracted Collectives  |  Next: SKTO's Medical Greens Announces New Distribution Agreement Taking Total Market Presence to Over 400 California Collectives